MX2021007646A - Inhibicion de la coagregacion especifica por arginina. - Google Patents

Inhibicion de la coagregacion especifica por arginina.

Info

Publication number
MX2021007646A
MX2021007646A MX2021007646A MX2021007646A MX2021007646A MX 2021007646 A MX2021007646 A MX 2021007646A MX 2021007646 A MX2021007646 A MX 2021007646A MX 2021007646 A MX2021007646 A MX 2021007646A MX 2021007646 A MX2021007646 A MX 2021007646A
Authority
MX
Mexico
Prior art keywords
arginine
disclosed
methods
commensal
pathogenic bacteria
Prior art date
Application number
MX2021007646A
Other languages
English (en)
Inventor
Carlo Daep
Harsh Mahendra Trivedi
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of MX2021007646A publication Critical patent/MX2021007646A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen métodos para inhibir selectivamente la coagregación de bacterias comensales y patógenas en una población de bacterias que comprende bacterias comensales y patógenas, tales como en la cavidad bucal de un individuo. Se describen métodos para reducir la biopelícula en la cavidad bucal de un individuo. Se describen métodos para inhibir la formación de biopelícula en una población de bacterias que comprende bacterias comensales y patógenas. También se describen métodos para identificar un compuesto o composición que mejora la inhibición selectiva de coagregación de bacterias comensales y patógenas por arginina o un oligómero de arginina. Se describen métodos para identificar un compuesto o composición que mejora la inhibición selectiva de formación de biopelícula de bacterias comensales y patógenas por arginina o un oligómero de arginina.
MX2021007646A 2018-12-26 2019-12-19 Inhibicion de la coagregacion especifica por arginina. MX2021007646A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785115P 2018-12-26 2018-12-26
PCT/US2019/067477 WO2020139698A1 (en) 2018-12-26 2019-12-19 Specific co-aggregation inhibition by arginine

Publications (1)

Publication Number Publication Date
MX2021007646A true MX2021007646A (es) 2021-08-11

Family

ID=69185706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007646A MX2021007646A (es) 2018-12-26 2019-12-19 Inhibicion de la coagregacion especifica por arginina.

Country Status (8)

Country Link
US (1) US20210196598A1 (es)
EP (1) EP3883558A1 (es)
CN (1) CN113226299A (es)
AU (1) AU2019416047B2 (es)
BR (1) BR112021012342A2 (es)
CA (1) CA3124651A1 (es)
MX (1) MX2021007646A (es)
WO (1) WO2020139698A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023240339A1 (en) * 2022-06-13 2023-12-21 Daniela Fischer Russell Oral health agent and composition for use in domestic animals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US8017657B1 (en) * 2001-09-07 2011-09-13 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US20030045473A1 (en) * 2002-07-19 2003-03-06 Sarama Robert Joseph Compositions, kits, and methods for cardiovascular health
CN100366294C (zh) * 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 一种口腔速溶制剂及其生产方法
JP2006199661A (ja) * 2005-01-24 2006-08-03 Sunstar Inc 共凝集阻害剤
PL2249784T3 (pl) * 2008-02-08 2016-12-30 Produkt do higieny jamy ustnej i sposoby jego stosowania i wytwarzania
WO2011123123A1 (en) 2010-03-31 2011-10-06 Colgate-Palmolive Company Oral care composition
ES2529216T3 (es) * 2010-06-23 2015-02-18 Colgate-Palmolive Company Composición oral terapéutica
CN108078798A (zh) 2012-12-05 2018-05-29 高露洁-棕榄公司 氟化物稳定的含锌组合物
US10206959B2 (en) * 2013-02-14 2019-02-19 University Of Florida Research Foundation, Inc. Probiotic arginolytic oral compositions and methods of making and using probiotic arginolytic oral compositions
CN115177607A (zh) * 2013-09-24 2022-10-14 密歇根大学董事会 用于破坏生物膜稳定性、改变生物膜和分散生物膜的组合物和方法
CN109908017A (zh) * 2013-12-19 2019-06-21 高露洁-棕榄公司 口腔护理组合物
CN104721226B (zh) 2013-12-19 2019-12-24 高露洁-棕榄公司 口腔护理组合物
CN107205895B (zh) 2015-07-01 2021-11-05 高露洁-棕榄公司 口腔护理组合物及使用方法

Also Published As

Publication number Publication date
US20210196598A1 (en) 2021-07-01
WO2020139698A1 (en) 2020-07-02
CA3124651A1 (en) 2020-07-02
EP3883558A1 (en) 2021-09-29
AU2019416047A1 (en) 2021-07-01
CN113226299A (zh) 2021-08-06
AU2019416047B2 (en) 2023-01-05
BR112021012342A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
MX2021007534A (es) Metodos para cambiar la biopelicula en la cavidad bucal de biopeliculas patogenas a sanas.
CR20110172A (es) Composiciones antimicrobianas
MA33197B1 (fr) Inhibiteurs de tripeptide époxy cétone protéases cristallines
CR8341A (es) Una composicion y metodo de tratamiento para condiciones urogenitales
DOP2021000044A (es) Moduladores de la expresión de pnpla3
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
PH12021550611A1 (en) Interleukin 10 Conjugates and Uses Thereof
MX2021000719A (es) Composicion de microbiota fecal, para su uso en la reduccion de la inflamacion inducida por tratamiento.
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
MX2021008727A (es) Tratamiento de la hepatotoxicidad.
AU2013408771A8 (en) Prebiotic oral care compositions containing an alkyl glycoside
MX2022000712A (es) Moduladores de nlrp3.
MX2022004024A (es) Metodos y materiales para el tratamiento de la neurotoxicidad.
CL2021001246A1 (es) Moduladores de expresión irf5.
PH12021551223A1 (en) Decarboxylase inhibitors for treating parkinson`s disease
MX2023003089A (es) Formas farmaceuticas solidas de bacterias.
ZA202103181B (en) Reduction of pathogenic bacteria using arginine
MX2021007646A (es) Inhibicion de la coagregacion especifica por arginina.
MX364736B (es) Composiciones bucales antisarro.
MX2020013510A (es) Composiciones para tratamiento, y metodos para fabricar y usar las mismas.
MX2021015301A (es) Métodos de cultivo celular y composiciones para la producción de anticuerpos.
JOP20210107A1 (ar) مضمنات التعبير عن foxp3